CA3065919A1 - Conjugues de construction d'anticorps - Google Patents

Conjugues de construction d'anticorps Download PDF

Info

Publication number
CA3065919A1
CA3065919A1 CA3065919A CA3065919A CA3065919A1 CA 3065919 A1 CA3065919 A1 CA 3065919A1 CA 3065919 A CA3065919 A CA 3065919A CA 3065919 A CA3065919 A CA 3065919A CA 3065919 A1 CA3065919 A1 CA 3065919A1
Authority
CA
Canada
Prior art keywords
immune
amino acid
conjugate
seq
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3065919A
Other languages
English (en)
Inventor
Peter Armstrong Thompson
Badreddin EDRIS
Craig Alan Coburn
Peter Robert Baum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARS Pharmaceuticals Inc
Original Assignee
Silverback Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silverback Therapeutics Inc filed Critical Silverback Therapeutics Inc
Publication of CA3065919A1 publication Critical patent/CA3065919A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Diverses compositions sont décrites. L'invention concerne également des compositions de conjugués composition-composé stimulateur immunitaire. L'invention concerne en outre les procédés de préparation et les utilisations de ces conjugués composition-composé stimulateur immunitaire. L'invention inclut des méthodes de traitement d'affections telles que le cancer.
CA3065919A 2017-06-07 2018-06-07 Conjugues de construction d'anticorps Abandoned CA3065919A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516667P 2017-06-07 2017-06-07
US62/516,667 2017-06-07
PCT/US2018/036560 WO2018227023A1 (fr) 2017-06-07 2018-06-07 Conjugués de construction d'anticorps

Publications (1)

Publication Number Publication Date
CA3065919A1 true CA3065919A1 (fr) 2018-12-13

Family

ID=64566685

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3065919A Abandoned CA3065919A1 (fr) 2017-06-07 2018-06-07 Conjugues de construction d'anticorps

Country Status (3)

Country Link
EP (1) EP3634401A1 (fr)
CA (1) CA3065919A1 (fr)
WO (1) WO2018227023A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111337685A (zh) * 2020-02-28 2020-06-26 苏州卫生职业技术学院 可溶性pd-l2作为sle生物标志物的应用

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
WO2018067702A1 (fr) 2016-10-04 2018-04-12 Massachusetts Institute Of Technology Copolymères en forme de goupillon et leurs utilisations
CA3084667A1 (fr) * 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Conjugue de construction d'anticorps-medicament pour le traitement de l'hepatite
CN119219654A (zh) * 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
BR112020023926A2 (pt) * 2018-05-25 2021-02-17 Silverback Therapeutics, Inc. compostos de amino-pirazinocarboxamida, conjugados e usos dos mesmos
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
AU2019365238A1 (en) * 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3693023A1 (fr) * 2019-02-11 2020-08-12 Sanofi Utilisation d'immuno-conjugués anti-ceacam5 pour le traitement du cancer du poumon
KR20210124260A (ko) * 2019-02-07 2021-10-14 사노피 폐암을 치료하기 위한 항-ceacam5 면역접합체의 용도
EP3937984A1 (fr) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugués ciblant le her2
KR20220056176A (ko) 2019-08-02 2022-05-04 메르사나 테라퓨틱스, 인코포레이티드 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
WO2021030358A1 (fr) 2019-08-12 2021-02-18 Regeneron Pharmaceuticals, Inc. Variants du récepteur 1 de la stimulation des macrophages (mst1r) et leurs utilisations
US20210130473A1 (en) * 2019-10-09 2021-05-06 Silverback Therapeutics, Inc. TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF
CA3163358A1 (fr) 2019-12-03 2021-06-10 Evotec International Gmbh Proteines de liaison a l'antigene associees a l'interferon et leurs utilisations
WO2021141662A1 (fr) * 2020-01-10 2021-07-15 Massachusetts Institute Of Technology Molécules chimériques ciblant la protéolyse (protacs) à bras fonctionnels et leurs utilisations
EP4097137A4 (fr) * 2020-01-30 2024-04-17 Oncternal Therapeutics, Inc. Combinaisons d'inhibiteurs d'egfr et d'inhibiteurs de ror1 pour le traitement du cancer
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
US12678512B2 (en) * 2020-03-06 2026-07-14 Daiichi Sankyo Company, Limited Anti-EGFR antibody-drug conjugate with a cyclic dinucleotide derivative
CN116196435B (zh) 2020-04-02 2025-12-02 梅尔莎纳医疗公司 包含sting激动剂的抗体药物缀合物
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
JP7849358B2 (ja) 2020-11-10 2026-04-21 サノフイ Ｃｅａｃａｍ５抗体－薬物コンジュゲート製剤
KR20230124037A (ko) * 2020-12-23 2023-08-24 소티오 바이오테크 에이.에스. 종양 특이적 claudin 18.2 항체-약물 접합체
EP4340858A4 (fr) * 2021-05-21 2025-08-13 Univ Columbia Compositions de nanocorps chimériques et méthodes de traitement associées
JP2024526259A (ja) 2021-07-02 2024-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｐｒｏｔａｃ抗体および複合体
CN113512117B (zh) * 2021-07-12 2023-08-22 武汉麦考津生物科技有限公司 一种可结合cd206的抗体及其应用
CN113563464B (zh) * 2021-08-01 2023-02-03 中国疾病预防控制中心性病艾滋病预防控制中心 人源化高中和活性抗新型冠状病毒单克隆抗体及应用
WO2023037268A1 (fr) * 2021-09-08 2023-03-16 Orum Therapeutics, Inc. Lieurs destinés à être utilisés dans des conjugués anticorps-médicament
WO2023056069A1 (fr) * 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation
CN115850485B (zh) * 2022-10-26 2025-08-08 苏州仁端生物医药科技有限公司 Claudin 16的单链抗体或其抗原结合部分及应用
IL321713A (en) 2022-12-27 2025-08-01 Merck Patent Gmbh Anti-PROTAC VHH antibodies and complexes
WO2024211154A2 (fr) * 2023-04-03 2024-10-10 Wisconsin Alumni Research Foundation Protacs ciblant la ferritine et procédés induisant la pyroptose
WO2024235273A1 (fr) * 2023-05-15 2024-11-21 成都社泰医疗科技有限公司 Composé de ciblage multiple et son utilisation
CN119306843A (zh) * 2023-07-13 2025-01-14 深圳泽安生物医药有限公司 多特异性抗体及其用途
WO2026015981A1 (fr) * 2024-07-16 2026-01-22 Immunobiochem Corporation Conjugués médicament-agent de dégradation et leurs procédés d'utilisation
WO2026059014A1 (fr) * 2024-09-13 2026-03-19 주식회사 파티앱젠 Anticorps anti-mésothéline humaine et son utilisation
CN121405806A (zh) * 2025-10-30 2026-01-27 中国人民解放军军事科学院军事医学研究院 一种具有增强的效应子功能的Fc变体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2549769T3 (es) * 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
WO2012012520A1 (fr) * 2010-07-20 2012-01-26 Washburn Therapeutics, Inc. Liaison améliorée de cytokines pro-inflammatoires par des conjugués polysaccharides-anticorps
SI3191135T1 (sl) * 2014-09-12 2021-01-29 Genentech, Inc. Anti-HER2 protitelesa in imunokonjugati
WO2016168766A1 (fr) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Commutateurs de lymphocytes t porteurs d'un récepteur chimérique et leurs utilisations
GB201506871D0 (en) * 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112018008918A8 (pt) * 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
US20170158772A1 (en) * 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
CN109152843A (zh) * 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111337685A (zh) * 2020-02-28 2020-06-26 苏州卫生职业技术学院 可溶性pd-l2作为sle生物标志物的应用

Also Published As

Publication number Publication date
EP3634401A1 (fr) 2020-04-15
WO2018227023A1 (fr) 2018-12-13

Similar Documents

Publication Publication Date Title
US12509526B2 (en) Anti-CD137 antibodies and uses thereof
EP3634401A1 (fr) Conjugués de construction d'anticorps
US20210115109A1 (en) Conjugates and methods of use thereof for selective delivery of immune-modulatory agents
ES2910365T3 (es) Nuevos polipéptidos biespecíficos contra CD137
US20190336615A1 (en) Tumor targeting conjugates and methods of use thereof
JP2026048631A (ja) マスクされたｉｌ－１２サイトカイン及びその切断産物
EP3864044A1 (fr) Anticorps b7h3 à domaine unique et compositions thérapeutiques associées
WO2020076977A2 (fr) Anticorps à domaine unique dll3 et compositions thérapeutiques
US20200199242A1 (en) Construct-peptide compositions and methods of use thereof
CN110741019A (zh) 特异性识别磷脂酰肌醇蛋白聚糖3的构筑体及其用途
TW201737941A (zh) 新穎的b7-h3-結合分子、其抗體藥物綴合物及其使用方法
CN110156893A (zh) 抗cd3抗体及使用方法
AU2019356806B2 (en) Antibody constructs binding 4-1BB and tumor-associated antigens and uses thereof
CN114341185A (zh) 抗间皮素抗体及其免疫缀合物
US20250051464A1 (en) Epha2 antibodies
CA3146977A1 (fr) Constructions d'anticorps se liant a 4-1bb et recepteurs alpha de folate et leurs utilisations
CN113811331A (zh) 抗csf1r抗体、il10融合蛋白及其用途
CA3226306A1 (fr) Nouvelles molecules multi-specifiques
WO2023094995A1 (fr) Anticorps humains cxcl16 et leur utilisation
CA3176246C (fr) Anticorps anti-tigit
US20250276077A1 (en) Epha2 antibodies
WO2025064951A1 (fr) Anticorps anti-tumoraux
HK40012721A (en) Anti-cd3 antibodies and methods of use

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220301